BIOMAT Database Logo BIOMAT Database Logo

Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts. 1991

N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Cyclosporine has been used as primary immunosuppression in renal allograft recipients in our unit for the past decade. The overall clinical experience and long-term effects of the agent are reviewed. There were 461 consecutive recipients of kidney grafts; 379 received grafts from cadaver donors (CAD) and 82 from living related donors (LRD). Four separate clinical protocols were used sequentially using progressively decreasing doses of CyA; azathioprine was added in group 4 recipients of LRD grafts, and in patients receiving secondary CAD grafts (group 5). The patient mortality rate was less than 5%, with sepsis being the prime contributor. The majority of kidney grafts were lost within the first 2 months after operation; those that never functioned were found almost invariably to have been irreversibly rejected. During the subsequent years of follow-up, attrition of CAD grafts was significantly greater than LRD grafts. In contrast, the attrition rate of primary and secondary CAD grafts was the same after the first 3 months, emphasizing the importance of early immunologic graft destruction. Primary nonfunction occurred in 49% of CAD kidneys and 17% of LRD grafts; however 71% of initially nonfunctioning LRD grafts never functioned at all compared to 34% of CAD grafts, the majority of such organs undergoing fulminate rejection. Individual graft loss after 1 year was almost inevitably due to chronic rejection; there were no differences in long-term allograft function among the treatment groups. Although CyA has improved overall results of kidney transplantation, chronic rejection remains a major unresolved problem.

UI MeSH Term Description Entries
D008297 Male Males
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D001900 Boston City located in Massachusetts.
D002423 Cause of Death Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint. Causes of Death,Death Cause,Death Causes
D002985 Clinical Protocols Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. Protocols, Clinical,Research Protocols, Clinical,Treatment Protocols,Clinical Protocol,Clinical Research Protocol,Clinical Research Protocols,Protocol, Clinical,Protocol, Clinical Research,Protocols, Clinical Research,Protocols, Treatment,Research Protocol, Clinical,Treatment Protocol
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections

Related Publications

N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
Cyclosporine monotherapy as primary immunosuppression in renal transplantation--five-year experience.
February 1994, Transplantation proceedings,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression.
March 1994, Transplantation,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
Ten-year experience with low-dose cyclosporine A in renal transplantation.
October 1994, Transplantation proceedings,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
Nocardiosis in renal transplant recipients undergoing immunosuppression with cyclosporine.
April 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
Ten years after: long-term effects of cyclosporine-based immunosuppression on renal allograft recipients.
November 1998, Transplantation proceedings,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
Ten year experience with pulmonary allografts in children.
July 1995, The Journal of heart valve disease,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
FK 506 conversion of renal allografts failing cyclosporine immunosuppression.
December 1991, Transplantation proceedings,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
Successful transplantation of 100 untransfused cyclosporine-treated primary recipients of cadaveric renal allografts.
January 1988, Transplantation,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
Infectious complications in renal transplant recipients: a 10-year review of cyclosporine-based immunosuppression.
November 1998, Transplantation proceedings,
N L Tilney, and A Chang, and E L Milford, and W D Whitley, and J M Lazarus, and E L Ramos, and T B Strom, and C B Carpenter, and R L Kirkman
FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression.
February 1993, Transplantation proceedings,
Copied contents to your clipboard!